IP Library › Granted Patent US 10,358,501
Granted Patent B2
US 10,358,501 · App. 15/643,690 · Granted Jul 23, 2019

HER3 specific monoclonal antibodies for diagnostic and therapeutic use

Inventors: Ningyan Zhang (Houston, TX); Zhiqiang An (Houston, TX)
Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
C07K16/32A61F7/10A61K39/39558A61K45/06A61N5/10G01N33/57484G01N33/57492A61K2039/505C07K2317/14C07K2317/24C07K2317/55C07K2317/565C07K2317/73C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,358,501
App. No.
15/643,690
Granted
Jul 23, 2019
Kind
B2
Abstract

Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Claims (82)

1. One or more nucleic acids encoding a monoclonal antibody, wherein the antibody specifically binds to HER3, competes for binding of the HER3 epitopes with a Rab46, Rab1210, Rab189, or Rab774 monoclonal antibody, and comprises:

(i) (a) a first V H CDR identical to SEQ ID NO: 9;

(b) a second V H CDR identical to SEQ ID NO: 10;

(c) a third V H CDR identical to SEQ ID NO: 11;

(d) a first V L CDR identical to SEQ ID NO: 12;

(e) a second V L CDR identical to SEQ ID NO: 13; and

(f) a third V L CDR identical to SEQ ID NO: 14,

or

(ii) (a) a first V H CDR identical to SEQ ID NO: 15;

(b) a second V H CDR identical to SEQ ID NO: 16;

(c) a third V H CDR identical to SEQ ID NO: 17;

(d) a first V L CDR identical to SEQ ID NO: 18;

(e) a second V L CDR identical to SEQ ID NO: 19; and

(f) a third V L CDR identical to SEQ ID NO: 20,

or

(iii) (a) a first V H CDR identical to SEQ ID NO: 21;

(b) a second V H CDR identical to SEQ ID NO: 22;

(c) a third V H CDR identical to SEQ ID NO: 23;

(d) a first V L CDR identical to SEQ ID NO: 24;

(e) a second V L CDR identical to SEQ ID NO: 25; and

(f) a third V L CDR identical to SEQ ID NO: 26,

or

(iv) (a) a first V H CDR identical to SEQ ID NO: 27;

(b) a second V H CDR identical to SEQ ID NO: 28;

(c) a third V H CDR identical to SEQ ID NO: 29;

(d) a first V L CDR identical to SEQ ID NO: 30;

(e) a second V L CDR identical to SEQ ID NO: 31; and

(f) a third V L CDR identical to SEQ ID NO: 32.

2. The one or more nucleic acids of claim 1 , wherein the antibody comprises:

(a) a first V H CDR identical to SEQ ID NO: 9;

(b) a second V H CDR identical to SEQ ID NO: 10;

(c) a third V H CDR identical to SEQ ID NO: 11;

(d) a first V L CDR identical to SEQ ID NO: 12;

(e) a second V L CDR identical to SEQ ID NO: 13; and

(f) a third V L CDR identical to SEQ ID NO: 14.

3. The one or more nucleic acids of claim 1 , wherein the antibody comprises:

(a) a first V H CDR identical to SEQ ID NO: 15;

(b) a second V H CDR identical to SEQ ID NO: 16;

(c) a third V H CDR identical to SEQ ID NO: 17;

(d) a first V L CDR identical to SEQ ID NO: 18;

(e) a second V L CDR identical to SEQ ID NO: 19; and

(f) a third V L CDR identical to SEQ ID NO: 20.

4. The one or more nucleic acids of claim 1 , wherein the antibody comprises:

(a) a first V H CDR identical to SEQ ID NO: 21;

(b) a second V H CDR identical to SEQ ID NO: 22;

(c) a third V H CDR identical to SEQ ID NO: 23;

(d) a first V L CDR identical to SEQ ID NO: 24;

(e) a second V L CDR identical to SEQ ID NO: 25; and

(f) a third V L CDR identical to SEQ ID NO: 26.

5. The one or more nucleic acids of claim 1 , wherein the antibody comprises:

(a) a first V H CDR identical to SEQ ID NO: 27;

(b) a second V H CDR identical to SEQ ID NO: 28;

(c) a third V H CDR identical to SEQ ID NO: 29;

(d) a first V L CDR identical to SEQ ID NO: 30;

(e) a second V L CDR identical to SEQ ID NO: 31; and

(f) a third V L CDR identical to SEQ ID NO: 32.

6. The one or more nucleic acids of claim 1 , wherein the antibody comprises:

(i) a V H domain at least about 80% identical to the V H domain of Rab46 (SEQ ID NO: 1); hRab46H-1 (SEQ ID NO: 33); or hRab46H-2 (SEQ ID NO: 34); and a V L domain at least about 80% identical to the V L domain of Rab46 (SEQ ID NO: 2); hRab46L-1 (SEQ ID NO: 35); or hRab46L-2 (SEQ ID NO: 36);

(ii) a V H domain at least about 80% identical to the V H domain of Rab1210 (SEQ ID NO: 3); hRab1210H-1 (SEQ ID NO: 37); or hRab1210H-2 (SEQ ID NO: 38); and a V L domain at least about 80% identical to the V L domain of Rab1210 (SEQ ID NO: 4); hRab1210L-1 (SEQ ID NO: 39); or hRab1210L-2 (SEQ ID NO: 40);

(iii) a V H domain at least about 80% identical to the V H domain of Rab189 (SEQ ID NO: 5) and a V L domain at least about 80% identical to the V L domain of Rab189 (SEQ ID NO: 6); or

(iv) a V H domain at least about 80% identical to the V H domain of Rab774 (SEQ ID NO: 7) and a V L domain at least about 80% identical to the V L domain of Rab774 (SEQ ID NO: 8).

7. The one or more nucleic acids of claim 6 , wherein the antibody comprises a V H domain at least 95% identical to the V H domain of hRab46H-1 (SEQ ID NO: 33) and a V L domain at least 95% identical to the V L domain of hRab46L-1 (SEQ ID NO: 35) or hRab46L-2 (SEQ ID NO: 36).

8. The one or more nucleic acids of claim 7 , wherein the antibody comprises a V H domain identical to the V H domain of hRab46H-1 (SEQ ID NO: 33) and a V L domain identical to the V L domain of hRab46L-1 (SEQ ID NO: 35).

9. The one or more nucleic acids of claim 7 , wherein the antibody comprises a V H domain identical to the V H domain of hRab46H-1 (SEQ ID NO: 33) and a V L domain identical to the V L domain hRab46L-2 (SEQ ID NO: 36).

10. The one or more nucleic acids of claim 6 , wherein the antibody comprises a V H domain at least 95% identical to the V H domain of hRab46H-2 (SEQ ID NO: 34) and a V L domain at least 95% identical to the V L domain of hRab46L-2 (SEQ ID NO: 36) or hRab46L-1 (SEQ ID NO: 35).

11. The one or more nucleic acids of claim 10 , wherein the antibody comprises a V H domain identical to the V H domain of hRab46H-2 (SEQ ID NO: 34) and a V L domain identical to the V L domain of hRab46L-2 (SEQ ID NO: 36).

12. The one or more nucleic acids of claim 10 , wherein the antibody comprises a V H domain identical to the V H domain of hRab46H-2 (SEQ ID NO: 34) and a V L domain identical to the V L domain of hRab46L-1 (SEQ ID NO: 35).

13. The one or more nucleic acids of claim 6 , wherein the antibody comprises a V H domain at least 95% identical to the V H domain of hRab1210H-1 (SEQ ID NO: 37)and a V L domain at least 95% identical to the V L domain of hRab1210L-1 (SEQ ID NO: 39) or hRab1210L-2 (SEQ ID NO: 40).

14. The one or more nucleic acids of claim 13 , wherein the antibody comprises a V H domain identical to the V H domain of hRab1210H- 1 (SEQ ID NO: 37) and a V L domain identical to the V L domain of hRab1210L-1 (SEQ ID NO: 39).

15. The one or more nucleic acids of claim 13 , wherein the antibody comprises a V H domain identical to the V H domain of hRab1210H-1 (SEQ ID NO: 37) and a V L domain identical to the V L domain of hRab1210L-2 (SEQ ID NO: 40).

16. The one or more nucleic acids of claim 6 , wherein the antibody comprises a V H domain at least 95% identical to the V H domain of hRab1210H-2 (SEQ ID NO: 38)and a V L domain at least 95% identical to the V L domain of hRab1210L-2 (SEQ ID NO: 40) or hRab1210L-1 (SEQ ID NO: 39).

17. The one or more nucleic acids of claim 16 , wherein the antibody comprises a V H domain identical to the V H domain of hRab1210H-2 (SEQ ID NO: 38) and a V L domain identical to the V L domain of hRab1210L-2 (SEQ ID NO: 40).

18. The one or more nucleic acids of claim 16 , wherein the antibody comprises a V H domain identical to the V H domain of hRab1210H-2 (SEQ ID NO: 38) and a V L domain identical to the V L domain of hRab1210L-1 (SEQ ID NO: 39).

19. The one or more nucleic acids of claim 6 , wherein the antibody comprises a V H domain identical to the V H domain of Rab189 (SEQ ID NO: 5) and a V L domain identical to the V L domain of Rab189 (SEQ ID NO: 6).

20. The one or more nucleic acids of claim 6 , wherein the antibody comprises a V H domain identical to the V H domain of Rab774 (SEQ ID NO: 7) and a V L domain identical to the V L domain of Rab774 (SEQ ID NO: 8).

21. The one or more nucleic acids of claim 1 , wherein the antibody is an IgG, IgM, IgA or an antigen binding fragment thereof.

22. The one or more nucleic acids of claim 1 , wherein the antibody is a Fab′, a F(ab′)2, a F(ab′)3, a monovalent scFv, or a bivalent scFv.

23. The one or more nucleic acids of claim 1 , wherein the antibody is a humanized antibody.

24. A host cell comprising the one or more nucleic acids according to claim 1 .

25. A method for producing an antibody comprising:

(a) expressing the one or more nucleic acids according to claim 1 encoding the VL and VH domains of an antibody in a cell; and

(b) purifying the antibody from the cell.

Continuity (3)
Division 14774808
Provisional Application 61782770 · Mar 14, 2013
Related Publication 20180066066A1 · Mar 8, 2018
Cited By (1)
US 12,245,355